In January of 2014, patient enrollment in its Phase 3 study of the CPX-351 in patients 60-75 years of age with high-risk (secondary) AML, reached 50% of the study’s planned enrollment of 300 patients (Filing 8-K , Celator Pharmaceuticals, MAY 12, 2014, View Source [SID:1234500519]). Patient enrollment is currently on track to be completed in the fourth quarter of 2014.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!